GlassScriptPhysician profile
Daniel R Mays
NPI 1003248444
$2,366.69
in general payments reported to CMS, 2019-2025
25 companies · $403 in 2025
The $403 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $276 · 2022: $335 · 2023: $687 · 2024: $665 · 2025: $403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,756.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,756.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $314.64 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $228.41 | 2021-2025 | |
| Dexcom, INC. | $175.84 | 2022-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $168.52 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $155.54 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $151.62 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.29 | 2021-2024 | Ofev |
| Boston Scientific Corporation | $126.93 | 2024-2025 | Wavewriter Alpha Prime 16, Rezum Generator, Bodyguardian |
| Smith+Nephew, INC. | $123.41 | 2023-2024 | Grafix, Renasys Touch |
| E.R. Squibb & Sons, L.L.C. | $115.18 | 2022-2025 | Camzyos, Eliquis |
| Lilly USA, LLC | $91.10 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Janssen Pharmaceuticals, INC | $90.05 | 2021-2022 | |
| Astellas Pharma US INC | $81.69 | 2023-2024 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $63.16 | 2023-2024 | Trelegy Ellipta |
| Amarin Pharma, INC. | $45.62 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $42.29 | 2022-2024 | Injectafer |
| Novartis Pharmaceuticals Corporation | $40.54 | 2023-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $39.45 | 2022 | |
| Xeris Pharmaceuticals, INC. | $32.33 | 2023 | Gvoke Hypopen |
| Amgen INC. | $32.07 | 2025 | Repatha, Repatha, Otezla |
| Kowa Pharmaceuticals America, INC. | $23.52 | 2021 | |
| Phathom Pharmaceuticals, INC. | $23.47 | 2025 | Voquezna |
| Dynavax Technologies Corporation | $17.98 | 2024 | Heplisav-B |
| Medtronic, INC. | $17.13 | 2024 | Intellis Adaptivestim |
| Tandem Diabetes Care, INC. | $16.91 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Mays listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.